Are impulse control disorders the last Parkinson’s ‘taboo’?
PD in Practice
Author: Almaz OhenePublished: 27 July 2017
Prep: Cook: Serves:
The National Institute for Clinical Excellence (NICE) in the UK has just updated their guidelines on Parkinson’s disease, including additional material on impulse control disorders. Matt Eagles – who was diagnosed with young-onset Parkinson’s at just eight years old – opens up about how his wedding was almost cancelled due to his gambling impulses caused by dopamine agonist patches, how his neurologist and bank intervened, and how he hopes that these new guidelines will encourage others to speak out
In just a few weeks in the winter of 2013, Matt Eagles gambled away thousands of pounds that he and his fiancée had saved for their wedding, set for the following spring.
He wasn’t trying to sabotage his relationship; he was suffering from an impulse control disorder caused by his Parkinson’s medication. Some 18 months previously, he had started using a ‘dopamine agonist’ – a skin patch that slowly releases dopamine-like medication to stimulate the brain cells.
The patch had been working well and had allowed him to work as a sports photographer at the London 2012 Olympic Games. However, Matt believes that an emotional trauma, in which he and his partner suffered the loss of a baby girl, triggered a change in the way the medication worked for him.
He suddenly found himself engrossed in gambling apps on his phone.
Matt, who has lived with Parkinson’s for more than 40 years, recalls: “I’d go to the bathroom just to play on fruit machines, video poker and roulette in secret – losing the money that my fiancée and I had saved.”
But sometimes he would win the money back again.
“One day I was sitting with my fiancée in the lounge, secretly playing video poker. I won about seven thousands pounds in just one hand. I must have pumped my fist and shouted, “Get in!” or something, as my fiancée asked me what I was so pleased about.
“At that moment, I had to admit what I’d been doing and was so ashamed of myself. My fiancée said, ‘But this isn’t you Matt’. Since we’d both taken time to research the side effects of my Parkinson’s medications, we put two and two together and decided that I must be suffering from an impulse control disorder.
“I have a very good relationship with my specialist in London, and so when we called the clinic it took us just a week to get an appointment. I was still gambling during that week, but not nearly as much since everything was all out on the open.”
Matt Eagles shooting women’s rugby
The doctor decided to wean Matt from the medication and reduced the size of his patch over two to three weeks.
“As the days went by, I felt fewer impulses to gamble, which was such a relief.”
Although, by now, Matt had all but stopped gambling, he still had the issue of the lost wedding fund to contend with.
“My fiancée and I talked it out and many tears were shed. It was touch-and-go at times. Fortunately, she still wanted to get married but only on the proviso that I get the treatment that I needed, which, realistically, meant that I wouldn’t be able to go back on the dopamine agonists.
“The drugs really did help with mobility, so coming off them has meant that my Parkinson’s is worse. But it’s a consequence that I’ve learned to live with. The medication was literally ruining my life.”
In addition to helping control movement, balance and walking, dopamine also plays an important role in the part of the brain that controls reward and motivation.
Some Parkinson’s medications, particularly dopamine agonists – medications that act like dopamine to stimulate your brain cells – and, in some cases, levodopa – have been linked to impulsive and compulsive behaviour behavioural patterns.
Research has shown that around 17% of people with Parkinson’s who take dopamine agonists experience impulsive and compulsive behaviour, although it is not clear exactly how the medications cause the changes in behaviour.
Medications affect people in different ways, but research suggests that you may be more likely to experience impulsive and compulsive behaviour if you are:
– someone with a history of addictive behaviour
– someone who has a family history of gambling or alcohol abuse
– a younger person with Parkinson’s
– a single person who lives alone
Matt believes that people with Parkinson’s should be prepared to share their stories of impulse control disorders to help break the taboos surrounding them.
“I know so many people that have suffered severe consequences from dopamine agonists– people who haven’t told their specialists or families, but have admitted to having problems within in their private Parkinson’s communities.”
He also thinks that institutes such as banks need to be prepared to offer help.
“I was lucky in that my specialist was wrote a letter to my bank stating that it was the drugs that were making me reckless with my money, so the largest of my debts actually got written off.”
Matt and his wife have now been married for three years. He is not currently using dopamine agonist patches and no longer has gambling issues.
Matt Eagles telling a joke on his wedding day
You can read the new NICE guidelines on Parkinson’s disease in full here and the section on impulse control disorders here
This month’s top Parkinson’s disease news stories from around the globe
3 weeks ago
Parkinson’s Europe co-founder Lizzie Graham wins World Parkinson Coalition award
Parkinson’s Europe co-founder Lizzie Graham has won a World Parkinson Coalition (WPC) award for her contribution to the Parkinson’s community. Lizzie is one of four people set to receive the Robin Elliott Award – which is given out every three years to individuals whose efforts best embody the goals and ethos of the WPC. She will be presented with the award in a ceremony at the World Parkinson’s Congress, which will be held in Barcelona later this year. Commenting on the news of Lizzie’s award, Parkinson’s Europe President, Veronica Clark, said: “Lizzie is Lizzie, and we love her for who she is and what she has done for us all – for people with Parkinson’s past and present and, I’m sure, future.” Lizzie co-founded the European Parkinson’s Disease Association (renamed Parkinson’s Europe last year) in 1992. She has since held several roles within the organisation – including secretary general and…
Study explores predictors of cognitive impairment in Parkinson’s disease
Cognitive impairment can affect some people with Parkinson’s – and may greatly impact their quality of life. Now, researchers in China have examined the possible risk factors for cognitive impairment in those with the condition. The study analysed data from 409 people with Parkinson’s within two years of their involvement in the Parkinson’s Progression Markers Initiative (PPMI) – an international study that follows people with and without the condition over time. The participants, who were newly diagnosed and experiencing normal cognitive function at the start of the research, were studied for at least five years. Published in ‘Frontiers in Aging Neuroscience’, the results indicate that older age at onset, high blood pressure and worse baseline motor symptoms may be among factors that could contribute to an increased risk of developing cognitive impairment. The researchers cautioned that “a larger sample and much more comprehensive assessment, and prolonged follow-up, will be required”.
Could frailty be a potential risk factor for Parkinson’s disease?
Frailty can refer to a reduction in physical function, and its attributes – including a slow walking speed and weak grip – are commonly experienced by people with Parkinson’s. Until now, there has been limited insight into the link between frailty and the risk of developing the condition over time. This is what led researchers at the Huazhong University of Science and Technology in China to analyse data from a large UK study, which was gathered over a 12-year period. Published in JAMA Neurology, the analysis found that frailty may be linked to an 87% higher risk of developing the condition. Commenting on the results, the researchers said: “These findings indicate that physical frailty is a potential risk factor for [Parkinson’s], and the assessment and management of frailty might have clinical significance in the at-risk population.”